NIAID HIV and Emerging Infectious Diseases Program
Healthy Volunteer Studies
Studies of healthy volunteers are crucial to the understanding and treatment of diseases. They provide a baseline for measuring the extent of disease and provide important information about the safety and effectiveness of various treatments.
(HIPP – Protocol #09-I-0226)
We will recruit 200 subjects, healthy individuals between 18 and 60 years of age who are eligible to donate blood. Individuals must have previously either recovered from novel H1N1 influenza or have been vaccinated against the infection. Eligible participants will undergo apheresis, an outpatient procedure in which researchers will collect plasma containing antibodies against the influenza virus by drawing blood into a special machine that separates blood cells from the liquid portion under sterile conditions and then returns the blood cells to the donor. Volunteers will be compensated.
(SAMOSA – Protocol #11-I-0259)
We will recruit 68 subjects (and up to 68 of their intimate contacts) who are healthy individuals between 18 and 49 years of age; if you have an intimate contact participating, they must be between the ages of 18 and 65. Volunteers must be in good general health, and be willing to receive a live influenza vaccine. Volunteers must also be willing to spend 7 days hospitalized at the NIH, and to return for at least six visits up to 12 months following vaccination. Intimate contacts must come to the NIH for two visits. Volunteers will be compensated.
(AVI-7100, Protocol # 13-I-0029)
We will recruit 40 individuals for the single dose cohort, then 24 individuals for a multi-dose cohort later. We are looking for healthy volunteers between the ages of 18-60. The primary goal of this study is to evaluate a new anti-viral drug called AVI-7100 that might have activity against influenza virus. This drug is being studied and has not been approved by the Food and Drug Administration (FDA). This drug is given through a vein (IV), and is not like any of the drugs currently available for influenza. The drug binds to the genetic material of the virus and may keep a person who takes the drug from having a more serious case of the flu. Volunteers will be compensated.
(NAAN, Protocol 13-I-0081)
The purpose of this study is to test an experimental vaccine to see if it is safe. The vaccine uses a live adenovirus as a carrier (or transporter). We hope that the adenovirus carrier will help the vaccine stimulate an immune response. An immune response is the body’s release of cells and substances that protect the body from infection and foreign matter. Another important goal is to see whether different routes (ways) of giving the vaccine cause different immune responses. We also want to see if the adenovirus in the vaccine is contagious or spreads to others. Adenoviruses are naturally occurring viruses that typically cause symptoms of a cold or conjunctivitis (a superficial eye infection). If we find a safe dose (amount) of adenovirus virus to stimulate the immune system, we hope to use this as a carrier for future vaccines to help prevent diseases such as malaria or HIV. Volunteers will be compensated.
back to top